SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.
SpectraCure AB (SPEC) - Total Liabilities
Latest total liabilities as of December 2025: Skr10.92 Million SEK
Based on the latest financial reports, SpectraCure AB (SPEC) has total liabilities worth Skr10.92 Million SEK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SpectraCure AB - Total Liabilities Trend (2013–2025)
This chart illustrates how SpectraCure AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SpectraCure AB Competitors by Total Liabilities
The table below lists competitors of SpectraCure AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
i2S SA
PA:ALI2S
|
France | €7.41 Million |
|
Suparma Tbk
JK:SPMA
|
Indonesia | Rp1.07 Trillion |
|
Caely Holdings Bhd
KLSE:7154
|
Malaysia | RM23.51 Million |
|
Witbe Net SA
PA:ALWIT
|
France | €16.43 Million |
|
Polychem Indonesia Tbk
JK:ADMG
|
Indonesia | Rp44.23 Million |
|
Top Gum Industries Ltd
TA:TPGM
|
Israel | ILA85.07 Million |
|
Tuktu Resources Ltd.
V:TUK
|
Canada | CA$10.87 Million |
|
Clientele
JSE:CLI
|
South Africa | ZAC14.17 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down SpectraCure AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SpectraCure AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SpectraCure AB (2013–2025)
The table below shows the annual total liabilities of SpectraCure AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr10.92 Million | -22.83% |
| 2024-12-31 | Skr14.15 Million | -5.53% |
| 2023-12-31 | Skr14.97 Million | +23.56% |
| 2022-12-31 | Skr12.12 Million | -18.33% |
| 2021-12-31 | Skr14.84 Million | +11.42% |
| 2020-12-31 | Skr13.32 Million | +7.31% |
| 2019-12-31 | Skr12.41 Million | +208.01% |
| 2018-12-31 | Skr4.03 Million | +209.74% |
| 2017-12-31 | Skr1.30 Million | -80.46% |
| 2016-12-31 | Skr6.66 Million | +542.83% |
| 2015-12-31 | Skr1.04 Million | -88.04% |
| 2014-12-31 | Skr8.66 Million | +269.23% |
| 2013-12-31 | Skr2.35 Million | -- |